Humab strives to improve health and well-being
for the humankind through genome engineering.
- We develop SynTheseTM, a transgenic antibody platform, by utilizing our genome engineering technology.
- SynTheseTM is a powerful tool that can produce human monoclonal antibodies.
- Humab will lead development of new antibody drugs via collaboration or co-development with global pharmaceutical companies.
- Antibody drugs have evolved from humanized antibodies to fully-human antibodies.
- Two base platform technologies enable the development of fully-human antibodies: phage display and transgenic mouse platforms.
- About 75% of all the fully-human antibodies approved by FDA through 2017 were developed based on the transgenic platform. We believe it is the most effective technology for producing fully-human antibodies.